Outset Medical, Inc. — Director's Dealing 2021

May 6, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Outset Medical, Inc. (OM)
CIK: 0001484612
Period of Report: 2021-05-03

Reporting Person: Vazquez Martin (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-03	Common Stock	M	2932	$3.88	Acquired	12187	Direct
2021-05-03	Common Stock	M	2068	$3.88	Acquired	14255	Direct
2021-05-03	Common Stock	S	4224	$57.8896	Disposed	10031	Direct
2021-05-03	Common Stock	S	539	$58.8242	Disposed	9492	Direct
2021-05-03	Common Stock	S	237	$59.8059	Disposed	9255	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-03	Performance Stock Option (Right to Buy)	$3.88	M	2932	Disposed	2027-12-19	Common Stock (2932)	Direct
2021-05-03	Stock Option (Right to Buy)	$3.88	M	2068	Disposed	2027-12-19	Common Stock (2068)	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $57.46 to $58.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1).

F2: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $58.48 to $58.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2).

F3: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $59.77 to $60.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3).

F4: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020.

F5: This option vests 25% on October 9, 2018 and then in 36 monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting period.